WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206934

CAS#: 1702967-37-0 (free base)

Description: PSMA-617, also know as vipivotide tetraxetan. It is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development.

Price and Availability


USD 190
USD 1250

USD 350
USD 2650

USD 750
USD 4450

PSMA-617 TFA salt, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 206934
Name: PSMA617 TFA
CAS#: 1702967-37-0 (free base)
Chemical Formula: C57H75F12N9O24
Exact Mass: 1041.5019
Molecular Weight: 1498.25
Elemental Analysis: C, 45.70; H, 5.05; F, 15.22; N, 8.41; O, 25.63

Related CAS #: 1702967-37-0 (free base)   CAS# unknown (TFA salt)    

Synonym: PSMA-617; PSMA617; PSMA 617; PSMA617 TFA; PSMA617 triflouroacetic acid salt; vipivotide tetraxetan.

IUPAC/Chemical Name: (((S)-1-carboxy-5-((S)-3-(naphthalen-2-yl)-2-((1r,4S)-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)-L-glutamic acid tetra(trifluoroacetic acid)


InChi Code: InChI=1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32-,35-,37-,38-,39-/m0/s1


Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in water and ethanol.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28. PubMed PMID: 29262549; PubMed Central PMCID: PMC5732715.

2: von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2017 Dec 16. doi: 10.1007/s00259-017-3895-x. [Epub ahead of print] Review. PubMed PMID: 29247284.

3: Rahbar K, Ahmadzadehfar H, Boegemann M. (177)Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? Eur J Nucl Med Mol Imaging. 2017 Nov 21. doi: 10.1007/s00259-017-3892-0. [Epub ahead of print] PubMed PMID: 29164300.

4: Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F. Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017. PubMed PMID: 29158832; PubMed Central PMCID: PMC5695136.

5: Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Nov 13. doi: 10.1007/s00259-017-3877-z. [Epub ahead of print] PubMed PMID: 29134280.

6: Iori M, Capponi PC, Rubagotti S, Esposizione LR, Seemann J, Pitzschler R, Dreger T, Formisano D, Grassi E, Fioroni F, Versari A, Asti M. Labelling of (90)Y- and (177)Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis. Contrast Media Mol Imaging. 2017 May 25;2017:8160134. doi: 10.1155/2017/8160134. eCollection 2017. PubMed PMID: 29097938; PubMed Central PMCID: PMC5612754.

7: Han XD, Liu C, Liu F, Xie QH, Liu TL, Guo XY, Xu XX, Yang X, Zhu H, Yang Z. (64)Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget. 2017 May 26;8(43):74159-74169. doi: 10.18632/oncotarget.18276. eCollection 2017 Sep 26. PubMed PMID: 29088775; PubMed Central PMCID: PMC5650330.

8: Kelly JM, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Vallabhajosula S, Babich JW. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of (68)Ga(3+), (111)In(3+), (177)Lu(3+) and (225)Ac(3). Nucl Med Biol. 2017 Dec;55:38-46. doi: 10.1016/j.nucmedbio.2017.10.001. Epub 2017 Oct 3. PubMed PMID: 29055836.

9: von Eyben FE, Kiljunen T, Joensuu T, Kairemo K, Uprimny C, Virgolini I. (177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer. Oncotarget. 2017 Aug 2;8(39):66112-66116. doi: 10.18632/oncotarget.19805. eCollection 2017 Sep 12. PubMed PMID: 29029496; PubMed Central PMCID: PMC5630396.

10: Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19. doi: 10.1007/s00259-017-3848-4. Epub 2017 Oct 12. PubMed PMID: 29026946.

11: Du Y, Dizdarevic S. Molecular radiotheragnostics in prostate cancer. Clin Med (Lond). 2017 Oct;17(5):458-461. doi: 10.7861/clinmedicine.17-5-458. PubMed PMID: 28974599.

12: Dam JH, Olsen BB, Baun C, Høilund-Carlsen PF, Thisgaard H. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Mol Imaging Biol. 2017 Dec;19(6):915-922. doi: 10.1007/s11307-017-1121-7. PubMed PMID: 28924629.

13: Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M. Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride. Oncotarget. 2017 Feb 25;8(33):55567-55574. doi: 10.18632/oncotarget.15698. eCollection 2017 Aug 15. PubMed PMID: 28903443; PubMed Central PMCID: PMC5589682.

14: Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, Haberkorn U, Giesel FL. Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37. doi: 10.1007/s00259-017-3817-y. Epub 2017 Sep 11. PubMed PMID: 28891033; PubMed Central PMCID: PMC5700223.

15: Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S. doi: 10.2967/jnumed.116.186775. Review. PubMed PMID: 28864607.

16: Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, Haberkorn U, Kratochwil C. Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq. J Nucl Med. 2017 Aug 10. pii: jnumed.117.194209. doi: 10.2967/jnumed.117.194209. [Epub ahead of print] PubMed PMID: 28798031.

17: Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer. Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763. PubMed PMID: 28719450.

18: Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, Rahbar K. (177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670. doi: 10.1007/s00259-017-3751-z. Epub 2017 Jun 17. PubMed PMID: 28624848.

19: Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivanoğlu H, Alan Selçuk N. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68. doi: 10.4274/mirt.08760. PubMed PMID: 28613198; PubMed Central PMCID: PMC5472088.

20: Schlenkhoff CD, Essler M, Ahmadzadehfar H. Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617. Clin Nucl Med. 2017 Aug;42(8):639-640. doi: 10.1097/RLU.0000000000001715. PubMed PMID: 28574879.